GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
Status:
Not yet recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized study designed to compare genotype-guided dosing to usual
care in patients with pancreas cancer and colorectal cancer who are UGT1A1 intermediate
metabolizers (*1/*28) (heterozygotes) and usual UGT metabolizers (*1/*1). All patients will
be assessed for UGT1A1 genotype at screening and those with intermediate or usual UGT1A1
genotypes (*1/*28, *1/*1) will be randomized to genotype-guided dosing versus usual care.